Form 4: Chemours Director Joseph Kava Acquires 7,182 Stock Units

Director Joseph Kava acquired 7,182 stock units in The Chemours Company as part of a board compensation arrangement.

Summary

• Director Joseph Kava was granted 7,182 stock units on May 6, 2026.
• The units are part of a compensation plan and will convert one-for-one into common stock upon his separation from the Board.
• Following this transaction, the director's total beneficial ownership increased to 24,603.3891 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Increased alignment between director interests and shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Value of the equity is subject to market fluctuations in Chemours common stock price.

Future Outlook

The stock units will convert to common stock upon the director's separation from the Board of Directors.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to incentivize long-term board commitment and align director interests with those of shareholders.

Comparison to Industry Standards

• The grant of deferred stock units is consistent with standard compensation practices for non-employee directors in the chemical and materials sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity-based compensation grant.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Chemours, CC, Form 4, Insider Trading, Director Compensation, Equity Grant